Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ritter, M
Right arrow Articles by Neubauer, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ritter, M
Right arrow Articles by Neubauer, A
Haematologica, Vol 89, Issue 11, 1397-1399
Copyright © 2004 by Ferrata Storti Foundation

Letter

Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia

M Ritter, TD Kim, P Lisske, C Thiede, M Schaich, and A Neubauer

Reports on the prognostic impact of mutations in the RAS proto-oncogenes in patients with acute myeloid leukemia (AML) are conflicting. A peptide nucleic acid (PNA)-based technique was used on 232 AML samples to detect point mutations of the hotspots in N-RAS and K-RAS. No significant correlations between RAS mutations and clinical features, karyotype or FLT3 were found.


This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
B. Gilje, R. Heikkila, S. Oltedal, K. Tjensvoll, and O. Nordgard
High-Fidelity DNA Polymerase Enhances the Sensitivity of a Peptide Nucleic Acid Clamp PCR Assay for K-ras Mutations
J. Mol. Diagn., July 1, 2008; 10(4): 325 - 331.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. T. Bowen, M. E. Frew, R. Hills, R. E. Gale, K. Wheatley, M. J. Groves, S. E. Langabeer, P. D. Kottaridis, A. V. Moorman, A. K. Burnett, et al.
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years
Blood, September 15, 2005; 106(6): 2113 - 2119.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine
Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.